Rivaroxaban

  • 1 lab in 1 country
  • Human trial1
  • Humans1

Outcomes

2

Cognitive function

upin humans1

1 study
  1. Rivaroxaban improves cognitive function in humans (mean difference 2.56, 95% CI 1.11-4.01).

    Human trialafter successful left atrial appendage occlusion10 mg daily365 daysn = 164

    Half-dose rivaroxaban vs antiplatelet therapy for preventing silent cerebral embolism after left atrial appendage occlusion: the HALO-SCE trial

    European heart journal31 Aug 2026

Silent cerebral embolic lesions

downin humans1

1 study
  1. Rivaroxaban decreases silent cerebral embolic lesions in humans (12.2% vs. 31.7%).

    Human trialafter successful left atrial appendage occlusion10 mg daily365 daysn = 164

    Half-dose rivaroxaban vs antiplatelet therapy for preventing silent cerebral embolism after left atrial appendage occlusion: the HALO-SCE trial

    European heart journal31 Aug 2026

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 2Sep 2026: 0Oct 2026: 02 in 12 months